Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

OBJECTIVE SB5 is a biosimilar agent for adalimumab (ADA). The aim of this study was to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of SB5 in comparison with reference ADA in patients with rheumatoid arthritis (RA). METHODS In this phase III, randomized, double-blind, parallel-group study, patients with moderately to severely active RA despite treatment with methot...

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis

BACKGROUND Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The aim of this study was to explore the safety and efficacy of open-label tofacitinib following blinded treatment with adalimumab or tofacitinib for moderate to severe RA. METHODS Analyses included patients treated with adalimumab 40 mg once every 2 weeks or tofacitinib 10 mg twice daily ...

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

BACKGROUND A substantial proportion of patients with rheumatoid arthritis (RA) do not respond, or lose initial response, to adalimumab treatment. One explanation for non-response is that patients develop anti-adalimumab antibodies. OBJECTIVES To evaluate the incidence of formation of antibody against adalimumab and the association with serum adalimumab concentrations and clinical response. ...

Nocardia infection with adalimumab in rheumatoid arthritis.

Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.